Eleven Weeks Post-Implant and Asking for Another Thirty
At 4:45 on a Friday, Mr. Chen, 34, calls about pain 11 weeks after an implant was placed at site #19. He asks for 'another thirty of the oxycodone' because ibuprofen 'does nothing.' The chart shows two 30-tablet oxycodone 5 mg prescriptions in the last six weeks, the last one three weeks ago. A CURES query shows oxycodone 10 mg from an urgent care twelve days ago and alprazolam 1 mg from a psychiatrist filled last week. The implant site has not been examined since the two-week follow-up. He is a cash patient, has no primary care physician, and says, 'if you don't help me I'll find someone who will - and I'll report you.'
1. What should Dr. Okafor do before deciding whether to prescribe, and what does the CURES information change?
Read the worked answer
The first issue is diagnostic, not pharmaceutical. Pain that is escalating or unrelieved 11 weeks after implant placement is a red flag for infection, a failing or non-integrated implant, nerve injury, or a non-dental source. An opioid refill without an examination would treat a symptom while missing the cause.
Before any prescription:
- Get him seen - same-day emergency slot, or direct him to urgent care or an on-call oral surgeon if the office cannot accommodate him. Do not leave him without a plan.
- Review CURES, which California requires before prescribing a Schedule II-IV controlled substance and periodically during continuing therapy; here it reveals a second opioid prescriber and a concurrent benzodiazepine.
What CURES changes: the opioid-benzodiazepine combination materially raises overdose risk. It shifts the default from 'refill and reassess' to 'do not add opioid on top of this without strong justification,' and it triggers offering naloxone and a conversation about risk, storage, and disposal. It also flags that another prescriber is involved, which warrants coordination rather than accusation.
Document the CURES review, the examination findings, and the clinical reasoning either way.
2. Is a straight opioid refill defensible? What alternatives and risk-reduction steps should be offered, and how should the threat be handled?
Read the worked answer
A refill alone is not defensible. It would add a third opioid supply to a patient already receiving opioids and a benzodiazepine from other prescribers, without an examination, for a complaint that suggests a treatable cause.
Offer instead: scheduled NSAID plus acetaminophen dosing (screen for contraindications), local measures, antibiotics if infection is confirmed, drainage or implant remediation, referral to oral surgery, endodontics, or a pain specialist, and coordination with the urgent care and psychiatrist with a signed authorization.
If an opioid is genuinely indicated after examination: lowest effective dose, shortest supply, no refills, one prescriber, CURES documented, naloxone offered, written aftercare and warning signs, and a defined follow-up. Electronic prescribing is the California default for controlled substances, subject to statutory exceptions.
The threat: it does not change the clinical decision and should not be answered with retaliation. Do not abruptly abandon him - dismissal requires written notice, emergency coverage, and time to transfer, and abandonment creates its own liability. Say plainly what you will do, put it in writing, and document the conversation, his statements, and the referrals offered.
Documented, reasoned, multimodal care is the defense; a chart that shows only a prescription is not.
3. What must be documented in this encounter, and are there any reporting obligations?
Read the worked answer
Document: the call and its time, the chief complaint, his description of the pain, the examination findings (or why none were possible), the CURES review and date, the other prescribers identified, the risk-benefit discussion, the alternatives offered, the rationale for whatever was or was not prescribed, the naloxone offer, referrals made, and his exact statements including the threat. Contemporaneous notes written Friday evening read very differently from a reconstructed chart months later.
Reporting: a patient's threat to complain is not, by itself, a reportable event and does not require notice to the board; it is a documentation issue. Nor is there a general duty to report suspected doctor-shopping - what exists is a duty to prescribe responsibly and to document your reasoning. If you later conclude a patient is obtaining controlled substances by fraud or forgery, that is a different analysis and counsel or local law enforcement guidance should be sought.
The practical protection is the record: it should show a dentist who examined, checked CURES, weighed the risks of combined opioid-benzodiazepine therapy, offered non-opioid and referral options, and did not abandon the patient. That chart answers both a board inquiry and a complaint.